According to the company, in the Phase 3 RASolute 302 trial, daraxonrasib showed a roughly 60 per cent reduction in the risk of death and a doubling of median overall survival compared with standard second-line chemotherapy. …
Oral RAS inhibitor doubles median survival and cuts death risk in metastatic pancreatic cancer
June 1, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 31 July
July 31, 2026 - - Podcast -
New partnership aims to create national blueprint for earlier Alzheimer’s diagnosis and care
July 31, 2026 - - Latest News -
Industry associations still resisting non-disclosure agreements for negotiation
July 31, 2026 - - Latest News -
AUScelerate programs channel major investment into heart and diabetes innovations
July 30, 2026 - - Latest News -
New AusBiotech membership aims to help Australia’s early-stage life sciences founders thrive
July 30, 2026 - - Latest News -
CSL begins clinical trials to test higher-yield plasma manufacturing
July 30, 2026 - - Latest News -
AI will likely grow the HTA 'industrial complex', but it can also democratise the institution
July 30, 2026 - - Latest News